$CCEL
CRYO CELL INTERNATIONAL INC

2021 Q2 Form 10-Q Financial Statement

#000156459021036760 Filed on July 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $7.205M $7.872M $7.621M
YoY Change -8.47% -3.15% 1.68%
Cost Of Revenue $2.223M $2.481M $2.503M
YoY Change -10.4% -5.62% 1.5%
Gross Profit $4.983M $5.391M $5.118M
YoY Change -7.58% -1.97% 1.76%
Gross Profit Margin 69.15% 68.49% 67.15%
Selling, General & Admin $3.148M $3.559M $3.870M
YoY Change -11.53% -2.45% 3.33%
% of Gross Profit 63.19% 66.01% 75.62%
Research & Development $3.237K $9.821K $5.722K
YoY Change -67.04% 98.12% -2.75%
% of Gross Profit 0.06% 0.18% 0.11%
Depreciation & Amortization $318.7K $95.11K $95.76K
YoY Change 235.12% -8.04% -8.69%
% of Gross Profit 6.4% 1.76% 1.87%
Operating Expenses $3.152M $3.568M $3.876M
YoY Change -11.68% -2.31% 3.32%
Operating Profit $1.995M $1.752M $1.249M
YoY Change 13.86% 252.86% 46.32%
Interest Expense $341.4K $365.4K $365.3K
YoY Change -6.56% -13.89% -10.23%
% of Operating Profit 17.11% 20.85% 29.25%
Other Income/Expense, Net -$353.9K -$418.8K -$309.7K
YoY Change -15.51% 6.86% -34.54%
Pretax Income $1.641M $1.333M $939.3K
YoY Change 23.09% 1174.52% 146.84%
Income Tax $470.6K $380.0K $252.4K
% Of Pretax Income 28.67% 28.5% 26.87%
Net Earnings $1.171M $953.3K $687.0K
YoY Change 22.79% 1676.2% 149.01%
Net Earnings / Revenue 16.25% 12.11% 9.01%
Basic Earnings Per Share $0.15 $0.13 $0.09
Diluted Earnings Per Share $0.14 $0.12 $0.08
COMMON SHARES
Basic Shares Outstanding 7.951M 7.546M 7.541M
Diluted Shares Outstanding 8.274M 8.112M 8.128M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.021M $9.325M $9.375M
YoY Change -13.98% 27.59% 18.9%
Cash & Equivalents $7.948M $8.420M $8.416M
Short-Term Investments $73.39K $905.4K $959.0K
Other Short-Term Assets $655.9K $241.9K $199.1K
YoY Change 171.19% -13.04% -2.85%
Inventory $890.4K $1.054M $1.103M
Prepaid Expenses $684.9K $451.7K
Receivables $5.216M $5.974M $5.767M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $14.78M $17.28M $16.89M
YoY Change -14.45% 15.18% -44.38%
LONG-TERM ASSETS
Property, Plant & Equipment $2.621M $1.739M $1.775M
YoY Change 50.73% -0.52% 21.17%
Goodwill $1.941M $1.941M
YoY Change 0.0% 0.0%
Intangibles $1.215M $1.232M
YoY Change -5.6% -6.25%
Long-Term Investments $308.0K $308.0K $308.0K
YoY Change 0.0% 0.0% 0.0%
Other Assets $41.98M $25.82M $26.06M
YoY Change 62.58% 6.97% 126.59%
Total Long-Term Assets $43.54M $27.56M $27.84M
YoY Change 57.96% 6.46% 114.68%
TOTAL ASSETS
Total Short-Term Assets $14.78M $17.28M $16.89M
Total Long-Term Assets $43.54M $27.56M $27.84M
Total Assets $58.32M $44.84M $44.73M
YoY Change 30.06% 9.66% 3.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.236M $951.9K $1.381M
YoY Change 29.87% -7.5% 36.7%
Accrued Expenses $1.491M $1.939M $2.714M
YoY Change -23.09% 100.91% -6.47%
Deferred Revenue $9.101M $8.840M $8.610M
YoY Change 2.96% 5.67% 4.15%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $3.100M $3.100M
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $20.12M $15.10M $16.07M
YoY Change 33.25% 10.93% 5.18%
LONG-TERM LIABILITIES
Long-Term Debt $326.3K $4.353M $5.106M
YoY Change -92.5% 205.47% 258.29%
Other Long-Term Liabilities $33.87M $34.72M $34.66M
YoY Change -2.46% -1.83% -4.51%
Total Long-Term Liabilities $34.20M $34.72M $34.66M
YoY Change -1.52% -5.63% -8.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.12M $15.10M $16.07M
Total Long-Term Liabilities $34.20M $34.72M $34.66M
Total Liabilities $54.32M $49.82M $50.73M
YoY Change 9.02% 1.72% -1.64%
SHAREHOLDERS EQUITY
Retained Earnings -$16.96M -$20.80M -$21.76M
YoY Change -18.5% -14.76% -11.05%
Common Stock $41.52M $36.38M $36.32M
YoY Change 14.12% 1.4% 1.46%
Preferred Stock
YoY Change
Treasury Stock (at cost) $20.56M $20.56M $20.56M
YoY Change 0.0% 5.07% 5.07%
Treasury Stock Shares $6.094M $6.094M $6.094M
Shareholders Equity $4.003M -$4.983M -$6.001M
YoY Change
Total Liabilities & Shareholders Equity $58.32M $44.84M $44.73M
YoY Change 30.06% 9.66% 3.2%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income $1.171M $953.3K $687.0K
YoY Change 22.79% 1676.2% 149.01%
Depreciation, Depletion And Amortization $318.7K $95.11K $95.76K
YoY Change 235.12% -8.04% -8.69%
Cash From Operating Activities $1.537M $822.2K $2.616M
YoY Change 86.95% 55.81% 41.07%
INVESTING ACTIVITIES
Capital Expenditures -$10.29K -$43.27K $6.961K
YoY Change -76.22% -87.97% -85.82%
Acquisitions
YoY Change
Other Investing Activities -$4.956M
YoY Change
Cash From Investing Activities -$4.967M -$43.27K -$6.961K
YoY Change 11377.98% -87.97% -85.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 99.67K -775.0K -734.0K
YoY Change -112.86% 0.0% -4.59%
NET CHANGE
Cash From Operating Activities 1.537M 822.2K 2.616M
Cash From Investing Activities -4.967M -43.27K -6.961K
Cash From Financing Activities 99.67K -775.0K -734.0K
Net Change In Cash -3.330M 3.930K 1.875M
YoY Change -84826.21% -100.65% 81.01%
FREE CASH FLOW
Cash From Operating Activities $1.537M $822.2K $2.616M
Capital Expenditures -$10.29K -$43.27K $6.961K
Free Cash Flow $1.547M $865.5K $2.609M
YoY Change 78.79% -2.48% 44.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2021-05-31
CY2020 dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4003118
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58318412
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1067664
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
299089
CY2021Q2 ccel Deposits And Other Assets
DepositsAndOtherAssets
579466
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Shell Company
EntityShellCompany
false
dei Trading Symbol
TradingSymbol
CCEL
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18819714
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26003118
CY2021Q2 us-gaap Assets
Assets
58318412
CY2020Q4 us-gaap Assets
Assets
46200094
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1236190
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
957390
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1491135
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2898211
CY2021Q2 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
301613
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275570
CY2021Q2 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
4889830
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9101008
CY2020Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20119776
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
29126311
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1230647
CY2020Q4 us-gaap Liabilities
Liabilities
48865229
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
326286
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
769021
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
136336
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32450608
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36581600
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
20563357
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
145330
CY2020Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
495029
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41982096
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41376640
CY2021Q2 us-gaap Treasury Stock Value
TreasuryStockValue
20563357
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16955495
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2665135
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46200094
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y5M26D
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2021Q2 ccel Duke License Agreement
DukeLicenseAgreement
15132189
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1181588
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11064034
CY2020Q4 us-gaap Goodwill
Goodwill
1941411
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
10363967
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2480543
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3558568
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-279205
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-23989
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-15088
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1376
us-gaap Share Based Compensation
ShareBasedCompensation
152572
us-gaap Share Based Compensation
ShareBasedCompensation
288752
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
105279
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
401679
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
35072
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
46818
ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
136116
ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
131351
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1002125
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
278805
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-261691
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7871844
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14065812
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15492618
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6581708
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4234868
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4983687
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7428597
us-gaap Depreciation And Amortization
DepreciationAndAmortization
288685
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-279205
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-23989
us-gaap Operating Income Loss
OperatingIncomeLoss
3230329
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9427
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15543
us-gaap Costs And Expenses
CostsAndExpenses
10835483
us-gaap Depreciation And Amortization
DepreciationAndAmortization
87524
us-gaap Costs And Expenses
CostsAndExpenses
12491362
CY2020Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-53572
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-15088
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1752186
us-gaap Operating Income Loss
OperatingIncomeLoss
3001256
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
105
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-12512
us-gaap Interest Expense
InterestExpense
621609
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1376
CY2020Q2 us-gaap Interest Expense
InterestExpense
365371
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
50
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
732
CY2021Q2 us-gaap Interest Expense
InterestExpense
341390
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-728562
us-gaap Interest Expense
InterestExpense
730670
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-636647
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13633638
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7545613
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1995068
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-353877
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-418838
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1641191
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6097331
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
32508511
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-293762
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
184615
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-108414
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
67754
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
61299
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-18519
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
113564
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
35340
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
278800
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-417259
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1407076
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-146354
ccel Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-133259
ccel Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-131185
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1842959
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1643589
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4199150
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3437755
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22272
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50228
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
5106224
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5128496
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50228
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2550000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1549999
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1066290
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
41000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1483710
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1508999
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2413056
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1878528
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10361125
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6541037
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7948069
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8419565
ccel Operating Lease Liability And Right Of Use Asset Due To Adoption Of Asc842
OperatingLeaseLiabilityAndRightOfUseAssetDueToAdoptionOfASC842
562775
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
904691
ccel Patent Option Agreement Credit To Purchase Of Patents And Licenses
PatentOptionAgreementCreditToPurchaseOfPatentsAndLicenses
500000
ccel Liabilities Incurred For The Purchase Of Patents And Licenses
LiabilitiesIncurredForThePurchaseOfPatentsAndLicenses
11258083
us-gaap Stock Issued1
StockIssued1
3585172
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-1695105
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4459840
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1170629
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4003118
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4651462
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
152572
us-gaap Net Income Loss
NetIncomeLoss
1864219
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4003118
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-6000627
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
953338
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-4982795
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6952851
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
288752
us-gaap Net Income Loss
NetIncomeLoss
1640304
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-4982795
CY2021Q2 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
27672
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
45934
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2021Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
38227319
CY2021Q2 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9101008
CY2021Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2017Q2 ccel Reimbursement Of Personal Expenses
ReimbursementOfPersonalExpenses
10000
CY2021Q2 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
8198
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
21705
CY2020Q2 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
11609
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
23144
CY2020Q2 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
22481
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
45801
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
499628
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322960
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9101008
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9183450
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
29126311
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
27200910
ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2020Q2 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2021Q2 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
466141
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
45934
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
12447
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
499628
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322960
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
18178409
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
19285813
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5215556
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36384360
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
8430850
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
6587891
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
45801
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
10461
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
38227319
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
398535
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
433875
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
17585653
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
17708527
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5974457
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
8703442
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
7059853
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
34152100
CY2020Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1284238
CY2021Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2021Q2 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2020Q2 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2021Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
153000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
289000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
68000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
64000
CY2020Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-54000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
1000
CY2021Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-13000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-15000
ccel Number Of Units Anticipated To Be Sold Each Year
NumberOfUnitsAnticipatedToBeSoldEachYear
17
ccel Percentage Of Decline In Annual Sales
PercentageOfDeclineInAnnualSales
0.03
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Palatino Linotype;font-style:normal;text-transform:none;font-variant: normal;">Product Warranty and Cryo-Cell Cares<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Program</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions.  Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients.  Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, PrepaCyte CB.  Additionally, under the Cryo-Cell Cares<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloablative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company.  The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.  </p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. The Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"> </p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4234868
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4983687
us-gaap Operating Income Loss
OperatingIncomeLoss
3230329
us-gaap Operating Income Loss
OperatingIncomeLoss
3001256
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7205195
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7871844
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2222671
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2480543
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1995068
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1752186
CY2021Q2 us-gaap Interest Expense
InterestExpense
341390
CY2020Q2 us-gaap Interest Expense
InterestExpense
365371
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14065812
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15492618
us-gaap Interest Expense
InterestExpense
621609
us-gaap Interest Expense
InterestExpense
730670
CY2021Q2 us-gaap Assets
Assets
58318412
CY2020Q4 us-gaap Assets
Assets
46200094
CY2020Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1284238
CY2021Q2 ccel Inventory Collection Kits
InventoryCollectionKits
41268
CY2020Q4 ccel Inventory Collection Kits
InventoryCollectionKits
33006
CY2021Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2021Q2 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
11882938
CY2020Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
11991352
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1596849
CY2021Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
32147
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
67219
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
3426286
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
5941214
CY2021Q2 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1181588
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
41000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
34000
CY2021Q2 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2021Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
15390
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
35072
CY2020Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
22337
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
46818
CY2021Q2 us-gaap Notes Payable
NotesPayable
3458433
CY2020Q4 us-gaap Notes Payable
NotesPayable
6008433
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
326286
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2841214
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
3426286
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
5941214
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
32894
us-gaap Interest Expense Debt
InterestExpenseDebt
73432
CY2021Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
15390
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
35072
CY2021Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
48284
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
108504
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
81604
us-gaap Interest Expense Debt
InterestExpenseDebt
191384
CY2020Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
22337
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
46818
CY2020Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
103941
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
238202
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1170629
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7765724
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
566676
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
953338
us-gaap Net Income Loss
NetIncomeLoss
1864219
us-gaap Net Income Loss
NetIncomeLoss
1640304
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7956301
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7545613
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7543376
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
322976
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
300292
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
577078
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8279277
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8112289
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8066016
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8120454
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.03
CY2021Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
705275
CY2021Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
4.96
CY2021Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
622865
CY2021Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
4.52
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
93380
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
30970
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.96
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
82410
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2020 and the remaining 1/3 on November 30, 2021.
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86549
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2021Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2021Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
In January 2021, the Company exercised its right to extend a lease for 36 months
CY2021Q1 ccel Lessee Operating Lease Extended Term Of Contract
LesseeOperatingLeaseExtendedTermOfContract
P36M
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
780070
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
780070
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P24M
CY2021Q2 ccel Additional Increase To Operating Lease Right Of Use Asset
AdditionalIncreaseToOperatingLeaseRightOfUseAsset
38072
CY2021Q2 ccel Additional Increase To Operating Lease Liabilities
AdditionalIncreaseToOperatingLeaseLiabilities
38072
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1067664
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
299089
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
301613
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275570
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
769021
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23632
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1070634
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
299202
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
165090
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
339182
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
313996
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
295086
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
24590
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
67310
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1070634
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
75564
us-gaap Operating Lease Payments
OperatingLeasePayments
147130
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
64886
us-gaap Operating Lease Payments
OperatingLeasePayments
131186
ccel Covid19
Covid19
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Palatino Linotype;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Note 12 – COVID-19</span></p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (“COVID-19”) outbreak.  The Company faces various risks related to health epidemics, pandemics and similar outbreaks, including the global outbreak of COVID-19.  The Company believes it has taken appropriate steps to minimize the risk to our employees and to maintain normal business operations and continues to actively monitor the global outbreak and spread of COVID-19 and continues to take steps to mitigate the potential risks to us posed by its spread and related circumstances and impacts.  Due to the change in consumer buying patterns as a result of COVID-19, the Company has experienced a decline in new client and public banking sales resulting in a decrease in revenues for the three and six months ended May 31, 2021 compared to the three and six months ended May 31, 2020.  While the ultimate health and economic impact of COVID-19 remains highly uncertain, we expect that our business operations and results of operations, including our net sales, earnings and cash flows, may continue to be impacted by decreases in new client and public banking sales.  We cannot predict the timing and speed of the recovery, and any delay in the recovery could significantly impact our future results. </p>
CY2020Q2 us-gaap Line Of Credit
LineOfCredit
350000
CY2020Q2 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000
CY2020Q4 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000

Files In Submission

Name View Source Status
0001564590-21-036760-index-headers.html Edgar Link pending
0001564590-21-036760-index.html Edgar Link pending
0001564590-21-036760.txt Edgar Link pending
0001564590-21-036760-xbrl.zip Edgar Link pending
ccel-10q_20210531.htm Edgar Link pending
ccel-10q_20210531_htm.xml Edgar Link completed
ccel-20210531.xsd Edgar Link pending
ccel-20210531_cal.xml Edgar Link unprocessable
ccel-20210531_def.xml Edgar Link unprocessable
ccel-20210531_lab.xml Edgar Link unprocessable
ccel-20210531_pre.xml Edgar Link unprocessable
ccel-ex311_8.htm Edgar Link pending
ccel-ex312_6.htm Edgar Link pending
ccel-ex313_9.htm Edgar Link pending
ccel-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending